VF
NKGN

Virtu Financial’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Virtu Financial’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,917
Closed -$24K – 2005
2024
Q2 		$24K Buy
+18,917
New +$26.4K ﹤0.01% 1012
2023
Q3 		– Sell
-12,332
Closed -$127K – 2027
2023
Q2 		$127K Buy
+12,332
New +$126K 0.01% 958
2023
Q1 		– Sell
-24,401
Closed -$243K – 2216
2022
Q4 		$243K Buy
24,401
+1,097
+5% +$10.8K 0.03% 603
2022
Q3 		$227K Buy
+23,304
New +$227K 0.02% 800

Other funds holding NKGN

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Virtu Financial's NKGN Position: Q3 2024 in Review

Virtu Financial sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2024, closing a stake of 18,917 shares — an estimated $24K sold.

Virtu Financial first reported a position in NKGN in Q3 2022 and held it in 4 quarters. The position peaked at $243K in Q4 2022. 19 funds tracked by Wall St. Rank hold NKGN as of Q3 2024.

  • Virtu Financial reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Virtu Financial sold 18,917 NKGen Biotech, Inc. Common Stock shares in Q3 2024, an estimated $24K.
  • Virtu Financial first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Virtu Financial's NKGen Biotech, Inc. Common Stock position peaked at $243K in Q4 2022.
  • 19 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2024.

Based on Virtu Financial's 13F filing for Q3 2024, filed 20 Nov 2024.